Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Ra Pharmaceuticals Inc (NQ: RARX )

47.99 USD UNCHANGED
Last Price Updated: 7:32 PM EDT, Apr 1, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Ra Pharmaceuticals Inc

< Previous 1 2 3 4 Next >
Shareholder Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders – RARX, PGNX, TSG, ROAN
From GlobeNewswire News Releases
RA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ra Pharmaceuticals, Inc. - RARX
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Ra Pharmaceuticals, Inc. (NasdaqGM: RARX) to... 
From Business Wire News Releases
STOCKHOLDER ALERT: Monteverde & Associates PC is Investigating the Following Merger
Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating: 
From PR Newswire
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Ra Pharmaceuticals, Inc. (NASDAQ: RARX) on Behalf of Ra Pharma Shareholders and Encourages Ra Pharma Investors to Contact the Fir
Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Ra Pharmaceuticals, Inc. (NASDAQ: RARX) on behalf of Ra Pharma shareholders concerning the proposed... 
From PR Newswire
SHAREHOLDER ALERT: WeissLaw LLP Investigates Ra Pharmaceuticals, Inc.
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Ra Pharmaceuticals, Inc. ("RARX" or the "Company") (NASDAQ: RARX) in connection with the... 
From PR Newswire
Ra Pharmaceuticals Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Ra Pharmaceuticals, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Fir
From GlobeNewswire News Releases
Ra Pharma (RARX) Alert: Johnson Fistel Investigates Proposed Sale of Ra Pharmaceuticals; Is $48 a Fair Price?
Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Ra Pharmaceuticals, Inc. (NASDAQ: RARX) ("Ra Pharma") breached their fiduciary duties in... 
From PR Newswire
UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases
- Will enhance UCB's leadership potential in myasthenia gravis by adding zilucoplan, a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside to UCB's... 
From PR Newswire
UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases
regulated information – inside information – UCB and Ra Pharmaceuticals Inc. (NASDAQ: RARX, Ra Pharma) announced today their entry into a merger agreement pursuant for which UCB will acquire Ra Pharma.... 
From Business Wire News Releases
Ra Pharmaceuticals Announces Dosing of First Patient in Global Phase 3 Pivotal Study of Zilucoplan for gMG
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the initiation of dosing in the RAISE study, its global, pivotal, Phase 3 clinical trial evaluating zilucoplan for the treatment of generalized... 
From Business Wire News Releases
Ra Pharmaceuticals Announces Selection for the First ALS Platform Trial by the Sean M. Healey & AMG Center for ALS at Mass General
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the selection of zilucoplan as one of the first clinical candidates to be evaluated in a pioneering platform trial for amyotrophic lateral... 
From Business Wire News Releases
Ra Pharmaceuticals Receives Orphan Drug Designation from the U.S. FDA for Zilucoplan for the Treatment of Myasthenia Gravis
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to zilucoplan for the treatment of myasthenia gravis. Ra Pharma... 
From Business Wire News Releases
Ra Pharmaceuticals Earns Clinical Development Milestone for Oral Macrocyclic Peptide Candidate Targeting Cardiovascular Indication Under Agreement with Merck
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that it has earned a clinical development milestone under its collaboration agreement with Merck, known as MSD outside the U.S. and Canada. The... 
From Business Wire News Releases
Ra Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced financial results for the second quarter ended June 30, 2019, and provided an update on recent corporate and clinical developments. 
From Business Wire News Releases
Ra Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Ra Pharmaceuticals, Inc. (Nasdaq: RARX) (“Ra Pharma”) today announced the closing of an underwritten public offering of 4,600,000 shares of its common stock, at a public offering price of $32.50 per... 
From Business Wire News Releases
Ra Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Ra Pharmaceuticals, Inc. (Nasdaq: RARX) (“Ra Pharma”) today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock, at a public offering price of $32.50 per... 
From Business Wire News Releases
Ra Pharmaceuticals Announces Proposed Public Offering of Common Stock
Ra Pharmaceuticals, Inc. (Nasdaq: RARX) (“Ra Pharma”) today announced that it intends to offer and sell, subject to market and other conditions, $100 million of its common stock in an underwritten... 
From Business Wire News Releases
Ra Pharmaceuticals and Camurus Announce Exclusive License Agreement for FluidCrystal® Extended Release Formulation of Zilucoplan
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) and Camurus AB (Nasdaq STO:CAMX) today announced an exclusive worldwide license agreement for the use of Camurus’s proprietary FluidCrystal® (FC) technology to... 
From Business Wire News Releases
Ra Pharmaceuticals and Camurus Announce Exclusive License Agreement for FluidCrystal® Extended Release Formulation of Zilucoplan
FluidCrystal® extended release formulation of zilucoplan achieved rapid and sustained pharmacodynamic inhibition of complement C5 in non-human primates, supporting at least once weekly dosing 
From PR Newswire
Ra Pharmaceuticals Announces Expansion of Neuromuscular Portfolio with Clearance of IND Application for Zilucoplan for the Treatment of Immune-Mediated Necrotizing Myopathy
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the U.S. Food and Drug Administration’s (FDA) clearance of the Company’s Investigational New Drug (IND) application for zilucoplan for the... 
From Business Wire News Releases
Ra Pharmaceuticals to Present at Upcoming Investor Conferences
Ra Pharmaceuticals, Inc. (Nasdaq: RARX) today announced that senior management will present at the following upcoming investor conferences: 
From Business Wire News Releases
Ra Pharmaceuticals to Present at Upcoming Investor Conferences
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that senior management will present at the following upcoming investor conferences: 
From Business Wire News Releases
Ra Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced financial results for the first quarter ended March 31, 2019, and provided an update on recent corporate and clinical developments. 
From Business Wire News Releases
Ra Pharmaceuticals Announces Positive gMG Phase 2 and Open-Label, Long-Term Extension Data at the 2019 AAN Annual Meeting
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the presentation of data from the Company’s Phase 2 clinical trial evaluating zilucoplan for the treatment of generalized myasthenia gravis (gMG),... 
From Business Wire News Releases
Ra Pharmaceuticals Presents Pre-Clinical Data for Zilucoplan XR at the 6th Annual Peptides Congress
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today presented pre-clinical data for an extended release (XR) formulation of zilucoplan at the 6th Annual Peptides Congress, taking place April 24-25, 2019, in... 
From Business Wire News Releases
Ra Pharmaceuticals Announces Completion of End-of-Phase 2 Interactions with FDA and Design of Pivotal Phase 3 gMG Study
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the successful completion of End-of-Phase 2 interactions with the U.S. Food and Drug Administration (FDA) for its Phase 3 clinical trial of... 
From Business Wire News Releases
Ra Pharmaceuticals Announces Acceptance of gMG Phase 2 and Open-Label, Long-Term Extension Data for Emerging Science Dual Presentation at the 2019 AAN Annual Meeting
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that data from its Phase 2 clinical trial of zilucoplan for the treatment of generalized myasthenia gravis (gMG) have been selected for an... 
From Business Wire News Releases
Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced financial results for the fourth quarter and year ended December 31, 2018, and provided an update on recent corporate and clinical developments. 
From Business Wire News Releases
Ra Pharmaceuticals to Present at the Cowen 39th Annual Health Care Conference
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that Doug Treco, Ph.D., President and Chief Executive Officer of Ra Pharma, will present at the Cowen 39th Annual Health Care Conference on... 
From Business Wire News Releases
Ra Pharmaceuticals Supports 12th Annual Rare Disease Day® and Joins Global Movement to Raise Awareness for Rare Diseases
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today joins forces with 30 million healthcare advocates around the world for the 12th Annual Rare Disease Day®, an awareness day dedicated to elevating public... 
From Business Wire News Releases
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.